Cell-Based Reparative Therapies for Multiple Sclerosis

Demyelinating Disorders (DN Bourdette and V Yadav, Section Editors)

DOI: 10.1007/s11910-013-0397-5

Cite this article as:
Ben-Hur, T., Fainstein, N. & Nishri, Y. Curr Neurol Neurosci Rep (2013) 13: 397. doi:10.1007/s11910-013-0397-5
Part of the following topical collections:
  1. Topical Collection on Demyelinating Disorders


The strong rationale for cell-based therapy in multiple sclerosis is based on the ability of stem and precursor cells of neural and mesenchymal origin to attenuate neuroinflammation, to facilitate endogenous repair processes, and to participate directly in remyelination, if directed towards a myelin-forming fate. However, there are still major gaps in knowledge regarding induction of repair in chronic multiple sclerosis lesions, and whether transplanted cells can overcome the multiple environmental inhibitory factors which underlie the failure of endogenous repair. Major challenges in clinical translation include the determination of the optimal cellular platform, the route of cell delivery, and candidate patients for treatment.


Stem cells Remyelination Immunomodulation Regeneration Cell-based reparative therapies Multiple sclerosis 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Neurology, The Agnes Ginges Center for Human NeurogeneticsHadassah Hebrew University Medical CenterJerusalemIsrael
  2. 2.Department of NeurologyHadassah University HospitalJerusalemIsrael

Personalised recommendations